JPWO2020005819A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020005819A5
JPWO2020005819A5 JP2020567827A JP2020567827A JPWO2020005819A5 JP WO2020005819 A5 JPWO2020005819 A5 JP WO2020005819A5 JP 2020567827 A JP2020567827 A JP 2020567827A JP 2020567827 A JP2020567827 A JP 2020567827A JP WO2020005819 A5 JPWO2020005819 A5 JP WO2020005819A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
residue
polypeptide
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020567827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528052A5 (https=
JP2021528052A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/038703 external-priority patent/WO2020005819A1/en
Publication of JP2021528052A publication Critical patent/JP2021528052A/ja
Priority to JP2024007979A priority Critical patent/JP7741903B2/ja
Publication of JP2021528052A5 publication Critical patent/JP2021528052A5/ja
Publication of JPWO2020005819A5 publication Critical patent/JPWO2020005819A5/ja
Pending legal-status Critical Current

Links

JP2020567827A 2018-06-25 2019-06-24 強力で選択的なインターロイキン模倣体のデノボ設計 Pending JP2021528052A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024007979A JP7741903B2 (ja) 2018-06-25 2024-01-23 強力で選択的なインターロイキン模倣体のデノボ設計

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862689769P 2018-06-25 2018-06-25
US62/689,769 2018-06-25
US201862768733P 2018-11-16 2018-11-16
US62/768,733 2018-11-16
PCT/US2019/038703 WO2020005819A1 (en) 2018-06-25 2019-06-24 De novo design of potent and selective interleukin mimetics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024007979A Division JP7741903B2 (ja) 2018-06-25 2024-01-23 強力で選択的なインターロイキン模倣体のデノボ設計

Publications (3)

Publication Number Publication Date
JP2021528052A JP2021528052A (ja) 2021-10-21
JP2021528052A5 JP2021528052A5 (https=) 2024-01-31
JPWO2020005819A5 true JPWO2020005819A5 (https=) 2024-01-31

Family

ID=67352582

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020567827A Pending JP2021528052A (ja) 2018-06-25 2019-06-24 強力で選択的なインターロイキン模倣体のデノボ設計
JP2024007979A Active JP7741903B2 (ja) 2018-06-25 2024-01-23 強力で選択的なインターロイキン模倣体のデノボ設計

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024007979A Active JP7741903B2 (ja) 2018-06-25 2024-01-23 強力で選択的なインターロイキン模倣体のデノボ設計

Country Status (13)

Country Link
US (8) US10703791B2 (https=)
EP (1) EP3810640A1 (https=)
JP (2) JP2021528052A (https=)
KR (1) KR20210025522A (https=)
CN (1) CN112739713A (https=)
AU (1) AU2019295637B2 (https=)
BR (1) BR112020025287A2 (https=)
CA (1) CA3102653A1 (https=)
IL (1) IL279415A (https=)
MX (1) MX2020014027A (https=)
PH (1) PH12020552140A1 (https=)
SG (1) SG11202011460YA (https=)
WO (1) WO2020005819A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3810640A1 (en) * 2018-06-25 2021-04-28 University of Washington De novo design of potent and selective interleukin mimetics
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP3883956A1 (en) * 2018-11-20 2021-09-29 University of Washington Split interleukin mimetics and their use
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス,インコーポレーテッド T細胞関連のがん細胞に結合する多機能性分子およびその使用
JP2022553370A (ja) * 2019-10-25 2022-12-22 ネオルーキン セラピューティクス,インコーポレイティド Il-2受容体作動薬の投与方法
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
EP4121449A2 (en) * 2020-03-16 2023-01-25 Neoleukin Therapeutics, Inc. Interleukin-2 receptor beta (il-2rb) binding polypeptides
CN114380919B (zh) * 2020-10-18 2024-06-25 北京志道生物科技有限公司 经修饰的il-2分子及其用途
CN112266413A (zh) * 2020-10-22 2021-01-26 中国人民解放军海军军医大学 扩增nk细胞并增强其杀伤活性的因子、饲养细胞系及方法
MX2023011310A (es) 2021-03-26 2023-10-05 Innate Pharma Anclajes de citocina para proteinas de celulas nk de union a nkp46.
BR112023025331A2 (pt) 2021-06-09 2024-02-27 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
CN113603791A (zh) * 2021-08-11 2021-11-05 厦门目青股权投资合伙企业(有限合伙) 一种融合蛋白及其应用
WO2023044318A2 (en) * 2021-09-15 2023-03-23 Neoleukin Therapeutics, Inc. Interleukin-2 receptor βeta (il-2rβ) binding polypeptides
WO2023052541A1 (en) * 2021-09-30 2023-04-06 Imcheck Therapeutics Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
EP4460512A4 (en) * 2022-01-07 2026-01-14 Cure Genetics Co Ltd NEW INTERLEUKIN-2 POLYPEPTIDES
IL314226A (en) * 2022-01-11 2024-09-01 Outpace Bio Inc Designed cytokine compositions and methods of use
AU2023215393A1 (en) * 2022-02-04 2024-08-15 The Board Of Trustees Of The Leland Stanford Junior University Surrogate cytokine polypeptides
CN114927160B (zh) * 2022-03-03 2024-09-27 北京晶泰科技有限公司 热点残基和靶点蛋白复合物结构的生成方法及装置
CN115124627B (zh) * 2022-06-20 2026-03-17 中国人民解放军海军军医大学 一种自分泌IL2Rβγ激动剂的MSLN-CAR-NK细胞及其应用
CN114773433B (zh) * 2022-06-23 2022-09-06 北京肿瘤医院(北京大学肿瘤医院) 一种cd25靶向多肽、分子探针及应用
CN119451978A (zh) * 2022-07-01 2025-02-14 神经基因治疗公司 Neo-2/15变体及其用于优先刺激T调节细胞的用途
WO2024177972A2 (en) * 2023-02-20 2024-08-29 The Wistar Institute Of Anatomy And Biology Antibody-cytokine chimeras
EP4722235A1 (en) * 2023-05-24 2026-04-08 Nantong Yichen Biopharma. Co. Ltd. Polypeptide, and conjugate and use thereof
CN119661643A (zh) * 2024-12-17 2025-03-21 北京肿瘤医院(北京大学肿瘤医院) 一种cd25靶向环状多肽、分子探针及应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
ES2300280T3 (es) 1999-12-08 2008-06-16 Amgen Inc. Moleculas de tipo interferon y usos de las mismas.
GB0019638D0 (en) * 2000-08-09 2000-09-27 European Molecular Biology Lab Embl Peptide mimetics
MXPA03011158A (es) * 2001-06-07 2004-02-27 Wyeth Corp Estructura de solucion de il - 13 y sus usos.
ATE442377T1 (de) * 2003-08-07 2009-09-15 Hoffmann La Roche Ra antigene peptide
CN1930300A (zh) 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
BRPI0617688A2 (pt) * 2005-10-21 2011-06-07 Hoffmann La Roche método para expressão recombinante de um polipeptìdeo
US9676871B2 (en) 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
US9428567B2 (en) 2010-12-22 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of interleukin-2 receptor
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
SG10201913396RA (en) * 2014-02-28 2020-03-30 Ichnos Sciences SA Expression constructs and methods for selecting host cells expressing polypeptides
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
US9777070B2 (en) 2014-04-30 2017-10-03 Pfizer Inc Anti-PTK7 antibody-drug conjugates
WO2016025385A1 (en) 2014-08-11 2016-02-18 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
WO2018153865A1 (en) 2017-02-24 2018-08-30 Philogen S.P.A. Immunoconjugates with optimized linkers and orientation
ES2894731T3 (es) 2017-03-15 2022-02-15 Silverback Therapeutics Inc Compuestos de benzazepina, conjugados y usos de los mismos
EP3810640A1 (en) * 2018-06-25 2021-04-28 University of Washington De novo design of potent and selective interleukin mimetics
EP3883585A4 (en) * 2018-11-20 2022-12-14 Innovative Cellular Therapeutics Holdings, Ltd. MODIFIED CELL EXPRESSING THERAPEUTIC AND USES THEREOF
EP3883956A1 (en) * 2018-11-20 2021-09-29 University of Washington Split interleukin mimetics and their use
JP2022553370A (ja) 2019-10-25 2022-12-22 ネオルーキン セラピューティクス,インコーポレイティド Il-2受容体作動薬の投与方法
US20230331858A1 (en) 2019-12-24 2023-10-19 Neoleukin Therapeutics, Inc. Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor
CN111040981A (zh) * 2019-12-26 2020-04-21 南昌大学 表达重组IL-2的重组大肠杆菌Nissle 1917及其功能验证方法
EP4121449A2 (en) 2020-03-16 2023-01-25 Neoleukin Therapeutics, Inc. Interleukin-2 receptor beta (il-2rb) binding polypeptides

Similar Documents

Publication Publication Date Title
JPWO2020005819A5 (https=)
JP2024056715A5 (https=)
US20250270279A1 (en) Polypeptide useful in adoptive cell therapy
JP2013510093A5 (https=)
JP7291196B2 (ja) 抗ヒトパピローマウイルス16 e7 t細胞受容体
RU2012123007A (ru) Конъюгаты меченных радиоактивным цирконием сконструированных антител с цистеиновыми заменами
JP3860398B2 (ja) サイトカインの免疫複合体
JP2008521920A5 (https=)
Maher et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor
US20210040228A1 (en) Chimeric cytokine receptor
Piechocki et al. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines
CA3154224A1 (en) T cell receptor recognising kras mutation and encoding sequence thereof
Liu et al. Hormone conjugated with antibody to CD3 mediates cytotoxic T cell lysis of human melanoma cells
US20220289820A1 (en) Chimeric cytokine receptor
CA3119472A1 (en) Split interleukin mimetics and their use
JP2013544253A5 (https=)
Weichselbaum et al. Gene therapy of cancer
Pameijer et al. Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor
US20200239545A1 (en) Receptor
ES2965437T3 (es) Células T modificadas genéticamente resistentes a fármacos y procedimientos de utilización de las mismas
JP2019527673A5 (https=)
Gerson et al. Gene therapy of cancer: translational approaches from preclinical studies to clinical implementation
KR20250024838A (ko) Kras g12v 돌연변이 폴리펩티드를 표적화하는 t 세포 수용체 및 이의 용도
Ma et al. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins
US20220195006A1 (en) Peptide markers to track genetically engineered cells